Evidence map›Paper›PMID 29406417›Full record

ReviewCurrent opinion in clinical nutrition and metabolic care2018

Is β-hydroxy β-methylbutyrate an effective anabolic agent to improve outcome in older diseased populations?

Mariëlle P K J Engelen, Nicolaas E P Deutz

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in clinical nutrition and metabolic care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03628365 (Can Beta-Hydroxy-beta-Methylbutyrate), which is not on this map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03628365 nacompletednot on this map

Can Beta-Hydroxy-beta-Methylbutyrate (HMB) Supplementation Counteract Muscle Catabolism in Critically Ill Patients? A Randomized Controlled Trial

TypeinterventionalSponsorMette M BergerRan2018 to 2020Enrolled37ConditionsCritical Illness, Muscle WeaknessArmsHMB (beta-hydroxy beta-methylbutyrate)
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Prospect of Muscle-Building Supplement HMB in Alzheimer's Disease.Journal of clinical & experimental immunology · 2026
    Article
  9. International society of sports nutrition position stand: β-hydroxy-β-methylbutyrate (HMB).Journal of the International Society of Sports Nutrition · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Update on the Etiology, Assessment, and Management of COPD Cachexia: Considerations for the Clinician.International journal of chronic obstructive pulmonary disease · 2022
    Review
  19. Article
  20. Multiomics-Identified Intervention to Restore Ethanol-Induced Dysregulated Proteostasis and Secondary Sarcopenia in Alcoholic Liver Disease.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Mariëlle P K J EngelenDepartment of Health and Kinesiology, Center for Translational Research in Aging & Longevity, Texas A&M University, College Station, Texas, USA.
Nicolaas E P Deutz
Texas A&M University · US

Funding

Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICUR01HL132887 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HEYLAND, DAREN KEITH, NEEDHAM, DALE MURRAY · 2017 to 2021
$3.5M
TARGETED GENOMICS FACILITY COREP30ES023512 · NIEHS · TEXAS A&M AGRILIFE RESEARCH · PI THREADGILL, DAVID W. · 2014 to 2017
$3.3M
NHLBI NIH HHS R01 HL132887NIEHS NIH HHS P30 ES023512
6 · The paper itself

Abstract

purpose of reviewβ-Hydroxy β-methylbutyrate (HMB) has been used for many years in athletes for muscle buildup and strength, and endurance enhancement. In recent years, its interest quickly expanded in older (diseased) populations and during (exercise) rehabilitation and recovery from hospitalization and surgery. We will discuss recent literature about HMB metabolism, its pharmacokinetics compared with the frequently used metabolite leucine, effectiveness of HMB to improve outcome in older diseased adults, and novel approaches for HMB use. RECENT

findingsHMB supplementation resulted in positive outcomes on muscle mass and functionality, related to its anabolic and anticatabolic properties and prolonged half-life time in blood. Furthermore, it was able to increase the benefits of (exercise) rehabilitation programs to enhance recovery from illness or medical procedures. There is promising evidence that HMB might support bone density, improve cognitive function, and reduce abdominal obesity, which is of importance particularly in the older (diseased) population. SUMMARY: The older diseased population might benefit from dietary HMB because of its established positive properties as well as its long lasting (pharmacological) effect. In addition to evaluating its efficacy and application in various clinical conditions, more research is needed into the mechanisms of action, the optimal dosage, and its potential additional beneficial effects on outcome.

Indexed as

AgingDietary SupplementsExerciseAnabolic AgentsAnimalsFemaleHumansImmune System DiseasesMaleMuscle, SkeletalMuscle StrengthNeoplasmsPulmonary Disease, Chronic ObstructiveRehabilitationValeratesAnabolic Agentsbeta-hydroxyisovaleric acidValerates

Identifiers

PMID29406417
PMCPMC5882564
OpenAlexW2793442106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.